Clinical trial
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic…
NCT00087776 · American Regent, Inc., Industry · Terminated
Key facts
| NCT number | NCT00087776 |
|---|---|
| Title | Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma |
| Official title | Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma |
| Lead sponsor | American Regent, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Taxoprexin, Dacarbazine |
| Enrollment | 393 |
| Start date | Dec 6, 2002 |
| Primary completion | Oct 27, 2007 |
| Completion | Oct 27, 2007 |
| First posted | Jul 16, 2004 |
| Last update posted | Jul 23, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: